Study on Using Gemcitabine and Docetaxel for Treating Low Grade Intermediate Risk Bladder Cancer

Inclusion Criteria

• Adults aged 18 and older.
• Diagnosed with low-grade intermediate risk bladder cancer, which includes:
  • Recurrent low-grade Ta
  • A single low-grade Ta tumor larger than 3 cm
  • Multiple low-grade Ta tumors
• In good general health with an ECOG performance status of 0 to 2.
• No signs of cancer in the upper urinary tract based on imaging tests.
• No cancer in the urethra based on a bladder examination.
• No visible cancer in the bladder within 60 days before joining the study.
• Neutrophil count of at least 1500 cells/mm³.
• If you have another type of cancer, it must not interfere with this study's treatment or safety assessments.
• Women who can become pregnant must use effective birth control during the study and for 6 months after the last treatment.
• Men with partners who can become pregnant must use effective birth control during the study and for 3 months after the last treatment.
• Must provide written consent to participate and follow study procedures.

Exclusion Criteria

• History of high-grade bladder cancer or cancer in the upper urinary tract.
• Previous treatment with BCG therapy in the bladder.
• Diagnosed with pure squamous cell carcinoma or adenocarcinoma.
• Any neuroendocrine carcinoma component.
• Physical issues that prevent placing a catheter in the urethra.
• Small bladder capacity that prevents treatment with the study drugs.
• Women who can become pregnant and are not willing to use birth control during the study and for 6 months after.
• Currently pregnant or breastfeeding.
• Any other health condition that could make the treatment unsafe or affect study results, as judged by the doctor.
• Received a live virus vaccine within 30 days before starting the study treatment.
• Individuals who are incarcerated or detained for psychiatric or physical illness.